- Home
- BBIO
as 10-28-2025 4:00pm EST
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | PALO ALTO |
| Market Cap: | 10.4B | IPO Year: | 2019 |
| Target Price: | $65.88 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $21.72 - $65.00 | Next Earning Date: | 10-29-2025 |
| Revenue: | $235,812,000 | Revenue Growth: | 7.62% |
| Revenue Growth (this year): | 115.12% | Revenue Growth (next year): | 65.29% |
Stock Insider Trading Activity of BridgeBio Pharma Inc. (BBIO)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Kumar Neil | BBIO | Chief Executive Officer | Oct 9 '25 | Sell | $54.80 | 40,000 | $2,192,092.00 | 835,686 | |
| Kumar Neil | BBIO | Chief Executive Officer | Oct 8 '25 | Sell | $54.74 | 40,000 | $2,191,350.21 | 835,686 | |
| Kumar Neil | BBIO | Chief Executive Officer | Sep 5 '25 | Sell | $52.97 | 40,000 | $2,122,047.40 | 835,686 | |
| MCCORMICK FRANK | BBIO | Director | Sep 5 '25 | Sell | $53.16 | 74,000 | $3,933,544.00 | 83,275 | |
| Kumar Neil | BBIO | Chief Executive Officer | Sep 4 '25 | Sell | $51.50 | 40,000 | $2,053,787.84 | 835,686 | |
| Trimarchi Thomas | BBIO | President and CFO | Aug 21 '25 | Sell | $49.48 | 42,237 | $2,090,081.05 | 421,081 | |
| Kumar Neil | BBIO | Chief Executive Officer | Aug 20 '25 | Sell | $49.03 | 26,156 | $1,276,927.17 | 835,686 | |
| Trimarchi Thomas | BBIO | President and CFO | Aug 18 '25 | Sell | $50.54 | 17,353 | $871,722.42 | 421,081 | |
| HOMCY CHARLES J | BBIO | N/A | Aug 11 '25 | Sell | $48.00 | 50,000 | $2,400,000.00 | 916,674 | |
| Kumar Neil | BBIO | Chief Executive Officer | Aug 8 '25 | Sell | $46.30 | 40,000 | $1,848,827.89 | 835,686 |
Latest BridgeBio Pharma Inc. News
BBIO Breaking Stock News: Dive into BBIO Ticker-Specific Updates for Smart Investing
Investor's Business Daily
16 days ago
This Pharma Play, The IBD Stock Of The Day, Is Offering Another Entry Amid 100% Advance This Year
Simply Wall St.
25 days ago
BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data
GlobeNewswire
a month ago
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Insider Monkey
a month ago
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch
Insider Monkey
a month ago
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics
MT Newswires
4 months ago
BridgeBio Pharma Sells Part of Beyonttra Royalty Rights for $300 Million
GlobeNewswire
4 months ago
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
MT Newswires
4 months ago
BridgeBio Pharma Insider Sold Shares Worth $4,422,800, According to a Recent SEC Filing
Compare BBIO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BBIO BridgeBio Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.